Advanced Filters
noise

Solid Tumor Clinical Trials

A listing of Solid Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,608 clinical trials
J Jie Wang, Professor

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.

18 - 70 years of age All Phase 2
J Jian Zhou, M.D., Ph.D.

A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.

17 - 85 years of age All Phase 1/2
C Christina Teng

A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors

Autism spectrum disorder (ASD) is an increasing public health concern, with preschool children often exhibiting persistent deficits in school readiness. However, targeted and developmentally comprehensive interventions remain limited. This randomized controlled trial will evaluate a 12-week Fundamental Movement Skills-CrossFit Training Program (FCTP) in 184 children with ASD aged 3-6 years, …

18 - 75 years of age All Phase 1
Z ZHENGBO SONG, DOCTORATE

A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors

The goal of the phase 1 study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics activity of FP008 in subjects with advanced solid tumors.

18 years of age All Phase 1

Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors

The goal of this study is to learn if BC008-1A given 900mg or 1200mg intravenously once every 3 weeks is safe and effective to treat patients with advanced esophageal cancer or advanced non-small cell lung cancer. It will also learn about the safety and pharmacokinetics of BC008-1A.

18 years of age All Phase 1

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD) and Recommended Cohort Expansion …

18 years of age All Phase 1
Z ZHENGBO SONG, DOCTORATE

A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors

This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HS387 in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib)

18 - 75 years of age All Phase 1

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.

18 - 99 years of age All Phase 1
j jian zhang, phD

A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are: What is the safety profile of JYP0035 when administered to these patients? How does JYP0035 …

18 - 74 years of age All Phase 1
S SHEN LIN

A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors

This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR) advanced solid tumors.

18 - 80 years of age All Phase 1

Simplify language using AI